Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Deurremidevir Hydrobromide for Oral Suspension in Infants and Young Children With Respiratory Syncytial Virus Infection

NCT07402512 is registered in ClinicalTrials.gov with Simcere Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07402512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07402512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Deurremidevir Hydrobromide for Oral Suspension in Infants and Young Children With Respiratory Syncytial Virus Infection
Lead sponsor
Simcere Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
March 11, 2026
Completion date
June 30, 2027
Enrollment
498 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus infection